Bansky G, Bühler H, Stamm B, Häcki W H, Buchmann P, Müller J
Dis Colon Rectum. 1987 Apr;30(4):288-92. doi: 10.1007/BF02556177.
Sixteen patients with 18 attacks of distal ulcerative colitis were treated randomly with either 0.5 mg topically administered beclomethasone dipropionate (BDP) or 5 mg betamethasone phosphate (BMT). The effect of the steroid enemas on adrenocortical function was examined by ACTH tests, which were performed before and 20 days after treatment. At completion of the trial, a marked suppression of the adrenocortical function was found in seven of eight patients treated for nine attacks with BMT but not in any patients in the BDP group (P less than 0.01). The mean posttreatment basal and stimulated plasma cortisol levels in the BMT group were significantly lower as compared with the BDP group. The overall therapeutic response assessed by score systems was comparable in the two treatment groups. It is concluded that, in the topical treatment of ulcerative colitis, BDP is preferable to BMT because it exerts an equal anti-inflammatory action without affecting adrenocortical function.
16例患有18次远端溃疡性结肠炎发作的患者被随机分为两组，分别接受局部给予0.5mg二丙酸倍氯米松（BDP）或5mg磷酸倍他米松（BMT）治疗。通过促肾上腺皮质激素（ACTH）试验检查类固醇灌肠剂对肾上腺皮质功能的影响，该试验在治疗前和治疗后20天进行。在试验结束时，在用BMT治疗9次发作的8例患者中，有7例发现肾上腺皮质功能受到明显抑制，而BDP组的任何患者均未出现这种情况（P小于0.01）。与BDP组相比，BMT组治疗后的基础血浆皮质醇水平和刺激后血浆皮质醇水平均显著降低。通过评分系统评估的总体治疗反应在两个治疗组中相当。得出的结论是，在溃疡性结肠炎的局部治疗中，BDP比BMT更可取，因为它具有同等的抗炎作用且不影响肾上腺皮质功能。
